Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVNNYSE:DNANASDAQ:MNMDNASDAQ:TARA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$6.49+3.7%$7.69$5.90▼$37.38$473.71M2.211.33 million shs1.94 million shsDNAGinkgo Bioworks$7.92+3.3%$7.17$5.00▼$33.20$459.75M1.291.47 million shs820,831 shsMNMDMind Medicine (MindMed)$6.60+0.8%$6.12$4.70▼$10.44$497.43M2.521.37 million shs660,046 shsTARAProtara Therapeutics$3.19+2.6%$3.93$1.60▼$10.48$123.08M1.73773,221 shs257,245 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas0.00%-1.82%-24.53%-64.55%-79.93%DNAGinkgo Bioworks0.00%+2.22%+1.11%-46.20%-77.77%MNMDMind Medicine (MindMed)0.00%+7.14%+14.38%-33.27%-27.23%TARAProtara Therapeutics0.00%-1.54%-18.21%-23.32%-14.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARVNArvinas3.6631 of 5 stars4.33.00.00.02.42.51.3DNAGinkgo Bioworks1.0652 of 5 stars0.83.00.00.02.52.51.3MNMDMind Medicine (MindMed)2.1206 of 5 stars3.71.00.00.03.30.80.6TARAProtara Therapeutics2.5136 of 5 stars3.52.00.00.03.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.60Moderate Buy$20.92222.29% UpsideDNAGinkgo Bioworks 1.67Reduce$5.77-27.21% DownsideMNMDMind Medicine (MindMed) 3.31Buy$25.11280.47% UpsideTARAProtara Therapeutics 3.00Buy$20.40539.50% UpsideCurrent Analyst Ratings BreakdownLatest TARA, MNMD, DNA, and ARVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ARVNArvinasUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $21.005/13/2025MNMDMind Medicine (MindMed)Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025ARVNArvinasMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $11.005/9/2025MNMDMind Medicine (MindMed)Chardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/5/2025ARVNArvinasCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.505/5/2025ARVNArvinasBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $10.005/5/2025ARVNArvinasTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$21.00 ➝ $11.005/2/2025ARVNArvinasBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$16.005/2/2025ARVNArvinasWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$26.00 ➝ $19.005/2/2025ARVNArvinasThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $8.005/2/2025ARVNArvinasGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $16.00(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$426.90M1.11N/AN/A$8.17 per share0.79DNAGinkgo Bioworks$237.42M1.94N/AN/A$21.93 per share0.36MNMDMind Medicine (MindMed)N/AN/AN/AN/A$1.90 per shareN/ATARAProtara TherapeuticsN/AN/AN/AN/A$6.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$198.90M-$0.66N/AN/AN/A-75.51%-33.75%-16.75%7/29/2025 (Estimated)DNAGinkgo Bioworks-$892.87M-$9.16N/AN/AN/A-298.78%-58.54%-34.24%N/AMNMDMind Medicine (MindMed)-$95.73M-$1.29N/AN/AN/AN/A-47.56%-35.55%N/ATARAProtara Therapeutics-$40.42M-$1.72N/AN/AN/AN/A-55.96%-49.06%8/5/2025 (Estimated)Latest TARA, MNMD, DNA, and ARVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025MNMDMind Medicine (MindMed)-$0.36-$0.35+$0.01-$0.35N/AN/A5/8/2025Q1 2025TARAProtara Therapeutics-$0.47-$0.29+$0.18-$0.29N/AN/A5/6/2025Q1 2025DNAGinkgo Bioworks-$1.23-$1.58-$0.35-$1.68$38.70 million$48.32 million5/1/2025Q1 2025ARVNArvinas-$0.93$1.14+$2.07$1.14$41.87 millionN/A3/12/2025Q4 2024TARAProtara Therapeutics-$0.57-$0.48+$0.09-$0.48N/AN/A3/6/2025Q4 2024MNMDMind Medicine (MindMed)-$0.33-$0.41-$0.08-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A4.644.64DNAGinkgo BioworksN/A5.795.79MNMDMind Medicine (MindMed)0.099.009.00TARAProtara TherapeuticsN/A9.859.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%DNAGinkgo Bioworks78.63%MNMDMind Medicine (MindMed)27.91%TARAProtara Therapeutics38.13%Insider OwnershipCompanyInsider OwnershipARVNArvinas4.73%DNAGinkgo Bioworks9.72%MNMDMind Medicine (MindMed)2.45%TARAProtara Therapeutics12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42072.99 million65.18 millionOptionableDNAGinkgo Bioworks64058.03 million51.89 millionOptionableMNMDMind Medicine (MindMed)4075.37 million71.68 millionOptionableTARAProtara Therapeutics3038.58 million18.05 millionOptionableTARA, MNMD, DNA, and ARVN HeadlinesRecent News About These CompaniesWith 73% ownership, Protara Therapeutics, Inc. (NASDAQ:TARA) boasts of strong institutional backingMay 16 at 3:35 PM | finance.yahoo.comIntegral Health Asset Management LLC Makes New $7.39 Million Investment in Protara Therapeutics, Inc. (NASDAQ:TARA)May 14, 2025 | marketbeat.comJ. Goldman & Co LP Takes $748,000 Position in Protara Therapeutics, Inc. (NASDAQ:TARA)May 14, 2025 | marketbeat.comProtara Therapeutics to Participate in Upcoming Investor ConferencesMay 13, 2025 | globenewswire.comDriehaus Capital Management LLC Makes New Investment in Protara Therapeutics, Inc. (NASDAQ:TARA)May 12, 2025 | marketbeat.comProtara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Buy" from BrokeragesMay 12, 2025 | marketbeat.comBarclays PLC Takes $492,000 Position in Protara Therapeutics, Inc. (NASDAQ:TARA)May 11, 2025 | marketbeat.comProtara Therapeutics, Inc. (NASDAQ:TARA) Given Average Rating of "Buy" by BrokeragesMay 11, 2025 | americanbankingnews.comProtara Therapeutics Reports Q1 2025 Financial ResultsMay 11, 2025 | tipranks.comProtara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comBlackstone Inc. Purchases Shares of 1,680,000 Protara Therapeutics, Inc. (NASDAQ:TARA)May 8, 2025 | marketbeat.com5AM Venture Management LLC Takes Position in Protara Therapeutics, Inc. (NASDAQ:TARA)May 4, 2025 | marketbeat.comAcorn Capital Advisors LLC Makes New Investment in Protara Therapeutics, Inc. (NASDAQ:TARA)May 4, 2025 | marketbeat.comRenaissance Technologies LLC Sells 194,440 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)May 4, 2025 | marketbeat.comRA Capital Management L.P. Buys 1,500,000 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)May 3, 2025 | marketbeat.comBoothbay Fund Management LLC Has $470,000 Holdings in Protara Therapeutics, Inc. (NASDAQ:TARA)May 3, 2025 | marketbeat.comHow Protara Therapeutics Reflects Shifts Among Nasdaq Companies by Market CapMay 3, 2025 | kalkinemedia.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2025 | globenewswire.comHC Wainwright Reiterates Buy Rating for Protara Therapeutics (NASDAQ:TARA)April 30, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Buys Shares of 2,250,000 Protara Therapeutics, Inc. (NASDAQ:TARA)April 30, 2025 | marketbeat.comProtara Therapeutics stock drops following interim trial resultsApril 29, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?3 Momentum Stocks That Could Soar Post-Market VolatilityBy Nathan Reiff | April 21, 2025View 3 Momentum Stocks That Could Soar Post-Market VolatilityTARA, MNMD, DNA, and ARVN Company DescriptionsArvinas NASDAQ:ARVN$6.49 +0.23 (+3.67%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$6.35 -0.14 (-2.14%) As of 05/16/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Ginkgo Bioworks NYSE:DNA$7.92 +0.25 (+3.29%) Closing price 05/16/2025 03:59 PM EasternExtended Trading$7.92 0.00 (-0.03%) As of 05/16/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Mind Medicine (MindMed) NASDAQ:MNMD$6.60 +0.05 (+0.76%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$6.46 -0.14 (-2.05%) As of 05/16/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.Protara Therapeutics NASDAQ:TARA$3.19 +0.08 (+2.57%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$3.22 +0.04 (+1.10%) As of 05/16/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Nextracker’s Solar Surge: Will It Shatter Its All-Time High? Savvy Investors Are Raising a Glass for Heineken Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
